Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Lung Cancer. 2007 Jul 3;58(1):95–103. doi: 10.1016/j.lungcan.2007.05.017

Table 4.

Responses rates (combined CR+PR) by type of EGFR mutation

Source (reference) EGFR Mutation p-value*
deletion 19 L858R
CR+PR/total (%) in 1st line therapy Inoue (43) 6/9 (67%) 6/7 (86%) 0.585
Asahina (44) 10/13 (77%) 2/3 (67%) 1
CR+PR/total (%) in mixed 1st subsequent lines of therapy Sutani (45) 15/20 (75%) 6/7 (86%) 1
Yoshida (46) 7/8 (87.5%) 12/13 (92.3%) 1
Sunaga (47) 15/16 (94%) 1/3 (33%) 0.050
CR+PR/total (%) in the combined group Total (99 patients) 53/66 (80.3%) 27/33 (81.8%) 1

EGFR, epidermal growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive

*

two-tailed probability by Fisher’s exact test